Eli Lilly & Co. (LLY) Tops Q1 EPS by $1.58, Beats on Revenue; Offers Strong Guidance

Eli Lilly & Co. (NYSE: LLY) reported Q1 EPS of $8.55, $1.58 better than the analyst estimate of $6.97. Revenue for the quarter came in at $19.8 billion versus the consensus estimate of $17.6 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2026 EPS of $35.50-$37.00, versus the consensus of $34.53. Eli Lilly & Co. sees FY2026 revenue of $82-85 billion, versus the consensus of $81.67 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• William Blair Downgrades On Holding AG (ONON) to Market Perform
• New Era Energy backs Texas data center oversight directive
• Coya Therapeutics, Inc. (COYA) Tops Q2 EPS by 42c